Sign up to save your podcasts
Or
Share HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer.
CME information and select publications here.
View all episodes
By Dr. Neil Love
4.9
5656 ratings
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer.
CME information and select publications here.
More shows like Oncology Today with Dr Neil Love
View all
JAMA Editors' Summary
141 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Breast Cancer Update
67 Listeners
Lung Cancer Update
32 Listeners
Hematologic Oncology Update
75 Listeners
Prostate Cancer Update
14 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
13 Listeners
Dermatologic Oncology Update
0 Listeners
Research To Practice | Oncology Videos
118 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,349 Listeners
The ONS Podcast
198 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
Two Onc Docs
190 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
41 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners